Astellas signs Asian licensing deal with Aquinox; Aravive touts early-stage PoC
→ Tokyo’s Astellas Pharma has inked a licensing deal with Vancouver’s Aquinox Pharmaceutical, snagging development and commercialization rights for Aquinox’s lead drug candidate rosiptor in Japan and other Asia-Pacific countries. The asset is a first-in-class, once-daily oral treatment that’s currently in Phase III trials for interstitial cystitis/bladder pain syndrome in North America and Europe. As part of the deal, Aquinox will get $25 million in an upfront payment, and up to $130 million in additional milestones plus royalties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.